Atorvastatin/aspirin/metoprolol/ramipril - Zydus Cadila

Drug Profile

Atorvastatin/aspirin/metoprolol/ramipril - Zydus Cadila

Latest Information Update: 07 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cadila Healthcare; Zydus Cadila
  • Class Antihyperlipidaemics; Antihypertensives; Antiplatelets; Class II antiarrhythmics; Fatty acids; Heptanoic acids; Heterocyclic bicyclo compounds; Ischaemic heart disorder therapies; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Propanolamines; Pyrroles; Salicylates; Small molecules
  • Mechanism of Action ACE inhibitors; Beta 1 adrenergic receptor antagonists; Cyclooxygenase inhibitors; HMG-CoA reductase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Ischaemic heart disorders

Most Recent Events

  • 07 Aug 2015 No recent reports on development identified - Phase-III for Ischaemic heart disorders in India (PO)
  • 26 Mar 2010 Cadila Healthcare and Zydus Cadila complete a phase III trial in Ischaemic heart disorders in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top